Close

CTI BioPharma (CTIC) Announces Pacritinib Phase 3 Met One co-Primary Endpoint; TSS Reduction Endpoint Missed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. SPY
4. LVS
5. INFY
6. CSX
7. TSLA
8. UAL
9. ISRG
10. NVDA


Go back to CTI BioPharma (CTIC) Announces Pacritinib Phase 3 Met One co-Primary Endpoint; TSS Reduction Endpoint Missed

Piper Remains Neutral on CTI BioPharma (CTIC) Update Top-Line PERSIST-2 Data

August 29, 2016 11:07 AM EDT

Piper Jaffray affirms CTI BioPharma Corp. (Nasdaq: CTIC) with a Neutral rating and $0.75 price target after CTIC announced positive top-line results... More